Date published: 2026-7-5

1-800-457-3801

SCBT Portrait Logo
Seach Input

UGT2B10 CRISPR/Cas9 KO Plasmid (h): sc-404210

0.0(0)
Write a reviewAsk a question

Datasheets
  • Target species: human
  • 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
  • UGT2B10 CRISPR/Cas9 Knockout (KO) Plasmid (h) is a pool of plasmids, each encoding Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed for maximum knockout efficiency using sequences derived from the GeCKO v2 library
  • gRNA sequences direct Cas9 to induce site-specific double-strand breaks (DSBs) in the UGT2B10 genomic locus, resulting in gene knockout through non-homologous end joining (NHEJ)
  • The puromycin resistance and RFP genes are flanked by LoxP sites, enabling removal of selection markers via Cre recombinase (Cre Vector: sc-418923) after establishing stable knockout cell lines
    Gene Editing Promo Banner

    Ordering Information

    Product NameCatalog #UNITPriceQtyFAVORITES

    UGT2B10 CRISPR/Cas9 KO Plasmid (h)

    sc-404210
    20 µg
    $397.00

    Overview

    UGT2B10 encodes a human UDP-glucuronosyltransferase that catalyzes glucuronidation reactions, increasing the solubility and facilitating clearance of endogenous metabolites and xenobiotics. As a phase II metabolic enzyme, UGT2B10 contributes to hepatic and extrahepatic detoxification pathways that regulate small-molecule homeostasis and chemical defense responses. Variation or altered expression of UGT2B10 can shift glucuronide conjugate profiles, impacting pharmacokinetics, metabolite-driven signaling, and cellular stress responses. These properties make UGT2B10 relevant to studies of drug metabolism, environmental exposure biology, and metabolic dysregulation associated with disease phenotypes.

    UGT2B10 CRISPR/Cas9 KO Plasmid (h) is a pool of plasmids designed for targeted disruption of the UGT2B10 gene in human cell lines. Each plasmid co-expresses a unique single guide RNA (sgRNA) targeting a distinct site within the UGT2B10 together with the Streptococcus pyogenes Cas9 nuclease. The plasmids also encode GFP, allowing fluorescent identification and enrichment of successfully transfected cells by fluorescence microscopy or flow cytometry.

    The multi-guide design increases the likelihood of generating insertions or deletions (indels) that disrupt the UGT2B10 open reading frame following Cas9-mediated double-strand break formation. DNA breaks introduced by the CRISPR/Cas9 system are repaired through endogenous non-homologous end joining (NHEJ) pathways, frequently resulting in frameshift mutations that abolish UGT2B10 protein expression.

    This CRISPR knockout system enables efficient generation of UGT2B10-deficient cell models for investigation of UGT2B10 signaling, functional genomics studies, cancer biology research, and evaluation of therapeutic responses in human cell lines.

    Key Features

    • sgRNAs targeting UGT2B10 exon(s) critical for UGT2B10 function
    • Co-expression of SpCas9 and sgRNA from a single plasmid for simplified delivery
    • GFP reporter for identification of transfected cells
    • Pool of plasmids targeting multiple UGT2B10 genomic sites to improve knockout efficiency
    • Compatible with delivery by transfection

    Design Variants

    CRISPRs +/- HDRs

    • gRNAs encoded by UGT2B10 CRISPR/Cas9 KO Plasmid (h) and UGT2B10 CRISPR/Cas9 KO Plasmid (h2) target distinct sites within the UGT2B10 locus. One or both targeting designs may be available. See Related Products for availability.
    • HDR donor constructs encoded by UGT2B10 HDR Plasmid (h) and UGT2B10 HDR Plasmid (h2) contain a puromycin resistance cassette and an RFP reporter flanked by UGT2B10 homology arms to support homology-directed repair at defined UGT2B10 target sites corresponding to the CRISPR/Cas9 KO designs. HDR donor availability may vary. See Related Products for availability.

    For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.